Sens. Amy Klobuchar, D-Minn.; Richard Blumenthal, D-Conn.; Cory Booker, D-N.J.; Mazie Hirono, D-Hawaii; Kamala Harris, D-Calif.; Elizabeth Warren, D-Mass.; Tammy Baldwin, D-Wash.; Tina Smith, D-Minn.; and Bernie Sanders, I-Vt.; yesterday urged the Federal Trade Commission to closely scrutinize pharmaceutical mergers. “In just the first half of 2019, we have seen multi-billion dollar acquisitions announced by Pfizer and Roche in addition to the proposed AbbVie and Bristol-Myers deals,” they . “And reports indicate that pharmaceutical mergers and acquisitions are expected to increase. This industry consolidation is occurring against a backdrop of ever rising prescription drug spending and reports that one in four people taking prescription drugs have difficulty affording their medication. It is more important than ever that the FTC take appropriate action to protect consumers from acquisitions that may threaten competition in drug markets, raise drug prices, or reduce patient access to essential medications.”

Related News Articles

Headline
The Department of Justice March 27 announced it is launching an Anticompetitive Regulations Task Force to advocate for “the elimination of anticompetitive…
Headline
A report released Jan. 9 by Kaufman Hall highlights hospital and health system merger and acquisition activity from last year.  The report said that…
Headline
The U.S. Chamber of Commerce Jan. 13 filed a lawsuit against the Federal Trade Commission, saying changes made by the FTC to premerger notification rules under…
Headline
The Federal Trade Commission Oct. 10 finalized changes to the premerger notification rules, form and instructions under the Hart-Scott-Rodino Antitrust…
Headline
The top three large-group insurers control an average of 82.2% of the market share in each state, nearly twice the combined average market share of each state’…
Headline
The Justice Department and the Federal Trade Commission Dec. 18 jointly issued the 2023 merger guidelines describing how the agencies review mergers and…